Afatinib, an ERBB family blocker, approved for the first-line treatment of advanced non-small cell lung cancer (NSCLC) with EGFR mutations, is one of the few TKIs with a low risk of cardiotoxicity [reviewed in (176)]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.